Innovative Therapy Focus InterMune specializes in developing treatments for orphan fibrotic diseases like idiopathic pulmonary fibrosis, offering unique opportunities to target niche markets with unmet medical needs in pulmonology.

Acquisition-backed Portfolio Since its acquisition by Roche for $8.3 billion in 2014, InterMune’s key product Esbriet has been integrated into a broader pharmaceutical pipeline, presenting potential partnerships or licensing opportunities within Roche’s extensive network.

Research & Development Leadership With ongoing Phase 3 clinical trials for IPF treatments, there is a continuous need for innovative support, diagnostics, and complementary therapies, creating avenues for sales in research collaborations or service provision.

Market Expansion Potential Having an approved medication in the EU and Canada and progressing towards US registration, InterMune is positioned for geographic market expansion, providing prospects for regional distributors, regulators, and market access partners.

Biotech Niche Player As a smaller organization with a focused research and development model, InterMune offers personal engagement opportunities for specialized biotech firms and suppliers interested in partnering with a dedicated innovator in pulmonology therapeutics.